[Research status of glucagon-like peptide-1 receptor agonists on obstructive sleep apnea]

Obstructive sleep apnea (OSA) is the most common sleep-disordered breathing disease. Continuous positive airway pressure (CPAP) is the gold standard for treatment, but compliance is suboptimal. Therefore, new therapeutic strategies need to be explored. OSA is often associated with multiple comorbidities, particularly type 2 diabetes and obesity. Effective weight loss is known to be crucial in reversing OSA and its associated comorbidities. However, sustained weight loss is difficult to achieve with lifestyle changes alone. Medications that have both hypoglycemic and weight-loss effects are one way to achieve this goal. This article discussed the therapeutic effect of glucagon-like peptide-1 receptor agonists on this disease.